EP ERA4Health Call 2027 “Multi-national Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Non-Communicable Respiratory Diseases, including Underrepresen­ted Populations”

The aim of the call is to support pragmatic, phase III, randomised controlled, multi-national interventional Investigator-Initiated Clinical Studies (IICS)

1. that are designed as following study types:

• comparative-effectiveness studies and/or
• drug repurposing studies of off-patent drugs

Applicants can make use of existing cohorts, e.g. for designing Trials within Cohorts (TwiCs).

2. that have a high public relevance in the fields of the following diseases or conditions (that are of equal importance):

• Cardiovascular diseases
• Metabolic disorders
• Autoimmune diseases
• Non-communicable respiratory diseases

The IICS should primarily address at least one of the abovementioned diseases/conditions, although a proposal can also address several of the mentioned diseases/conditions and/or in combination with related comorbidities.

3. that ensure inclusivity and diversity in the study population and also include sex/gender-sensitive, age-specific or other diversity-related aspects, if reasonable.

Further details as well as contact at the European Project Center of TU Dresden (EPC), can be found in the EPC’s news article.